ID   PDE3A_HUMAN             Reviewed;        1141 AA.
AC   Q14432; O60865; Q13348; Q17RD1;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2004, sequence version 3.
DT   12-APR-2017, entry version 161.
DE   RecName: Full=cGMP-inhibited 3',5'-cyclic phosphodiesterase A;
DE            EC=3.1.4.17;
DE   AltName: Full=Cyclic GMP-inhibited phosphodiesterase A;
DE            Short=CGI-PDE A;
GN   Name=PDE3A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Myocardium;
RX   PubMed=1315035; DOI=10.1073/pnas.89.9.3721;
RA   Meacci E., Taira M., Moos M. Jr., Smith C.J., Movsesian M.A.,
RA   Degerman E., Belfrage P., Manganiello V.;
RT   "Molecular cloning and expression of human myocardial cGMP-inhibited
RT   cAMP phosphodiesterase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3721-3725(1992).
RN   [2]
RP   SEQUENCE REVISION TO 12; 63-64 AND 354-371.
RA   Liu H., Manganiello V.;
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASN-12.
RC   TISSUE=Blood;
RX   PubMed=8695850;
RA   Cheung P.P., Xu H., McLaughlin M.M., Ghazaleh F.A., Livi G.P.,
RA   Colman R.W.;
RT   "Human platelet cGI-PDE: expression in yeast and localization of the
RT   catalytic domain by deletion mutagenesis.";
RL   Blood 88:1321-1329(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Penis;
RX   PubMed=10421499; DOI=10.1016/S0009-2797(99)00074-5;
RA   Kuthe A., Eckel H., Stief C.G., Uckert S., Forssmann W.-G., Jonas U.,
RA   Maegert H.-J.;
RT   "Molecular biological characterization of phosphodiesterase 3A from
RT   human corpus cavernosum.";
RL   Chem. Biol. Interact. 119:593-598(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PARTIAL PROTEIN SEQUENCE.
RX   PubMed=8155697; DOI=10.1016/0167-4838(94)90233-X;
RA   Degerman E., Moos M. Jr., Rascon A., Vasta V., Meacci E., Smith C.J.,
RA   Lindgren S., Andersson K.-E., Belfrage P., Manganiello V.;
RT   "Single-step affinity purification, partial structure and properties
RT   of human platelet cGMP inhibited cAMP phosphodiesterase.";
RL   Biochim. Biophys. Acta 1205:189-198(1994).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-520, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-312, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-312; SER-492 AND
RP   SER-520, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   INVOLVEMENT IN HTNB, VARIANTS HTNB ALA-445; ASN-445; SER-445; THR-447;
RP   VAL-447 AND VAL-449, AND CHARACTERIZATION OF VARIANTS HTNB ALA-445;
RP   ASN-445; SER-445; THR-447; VAL-447 AND VAL-449.
RX   PubMed=25961942; DOI=10.1038/ng.3302;
RA   Maass P.G., Aydin A., Luft F.C., Schaechterle C., Weise A.,
RA   Stricker S., Lindschau C., Vaegler M., Qadri F., Toka H.R., Schulz H.,
RA   Krawitz P.M., Parkhomchuk D., Hecht J., Hollfinger I.,
RA   Wefeld-Neuenfeld Y., Bartels-Klein E., Muehl A., Kann M., Schuster H.,
RA   Chitayat D., Bialer M.G., Wienker T.F., Ott J., Rittscher K.,
RA   Liehr T., Jordan J., Plessis G., Tank J., Mai K., Naraghi R.,
RA   Hodge R., Hopp M., Hattenbach L.O., Busjahn A., Rauch A., Vandeput F.,
RA   Gong M., Rueschendorf F., Huebner N., Haller H., Mundlos S.,
RA   Bilginturan N., Movsesian M.A., Klussmann E., Toka O., Baehring S.;
RT   "PDE3A mutations cause autosomal dominant hypertension with
RT   brachydactyly.";
RL   Nat. Genet. 47:647-653(2015).
CC   -!- FUNCTION: Cyclic nucleotide phosphodiesterase with a dual-
CC       specificity for the second messengers cAMP and cGMP, which are key
CC       regulators of many important physiological processes.
CC       {ECO:0000250|UniProtKB:Q9Z0X4}.
CC   -!- CATALYTIC ACTIVITY: Nucleoside 3',5'-cyclic phosphate + H(2)O =
CC       nucleoside 5'-phosphate.
CC   -!- COFACTOR:
CC       Name=a divalent metal cation; Xref=ChEBI:CHEBI:60240;
CC         Evidence={ECO:0000250};
CC       Note=Binds 2 divalent metal cations per subunit. Site 1 may
CC       preferentially bind zinc ions, while site 2 has a preference for
CC       magnesium and/or manganese ions. {ECO:0000250};
CC   -!- ENZYME REGULATION: Inhibited by cGMP.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- DISEASE: Hypertension and brachydactyly syndrome (HTNB)
CC       [MIM:112410]: A syndrome characterized by brachydactyly type E,
CC       severe salt-independent but age-dependent hypertension, an
CC       increased fibroblast growth rate, neurovascular contact at the
CC       rostral-ventrolateral medulla, and altered baroreflex blood
CC       pressure regulation. It results in death from stroke before age 50
CC       years when untreated. Brachydactyly type E is characterized by
CC       shortening of the fingers mainly in the metacarpals and
CC       metatarsals. {ECO:0000269|PubMed:25961942}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the cyclic nucleotide phosphodiesterase
CC       family. PDE3 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=PDE3 entry;
CC       URL="https://en.wikipedia.org/wiki/PDE3";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M91667; AAA35912.2; -; mRNA.
DR   EMBL; U36798; AAB18673.1; -; mRNA.
DR   EMBL; AJ005036; CAA06304.1; -; mRNA.
DR   EMBL; BC117369; AAI17370.1; -; mRNA.
DR   EMBL; BC117371; AAI17372.1; -; mRNA.
DR   CCDS; CCDS31754.1; -.
DR   PIR; A44093; A44093.
DR   RefSeq; NP_000912.3; NM_000921.4.
DR   UniGene; Hs.386791; -.
DR   UniGene; Hs.737522; -.
DR   PDB; 1LRC; Model; -; A=812-1017.
DR   PDBsum; 1LRC; -.
DR   ProteinModelPortal; Q14432; -.
DR   SMR; Q14432; -.
DR   BioGrid; 111165; 27.
DR   DIP; DIP-42197N; -.
DR   IntAct; Q14432; 15.
DR   MINT; MINT-3295914; -.
DR   STRING; 9606.ENSP00000351957; -.
DR   BindingDB; Q14432; -.
DR   ChEMBL; CHEMBL241; -.
DR   DrugBank; DB01223; Aminophylline.
DR   DrugBank; DB01427; Amrinone.
DR   DrugBank; DB00261; Anagrelide.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB01166; Cilostazol.
DR   DrugBank; DB04880; Enoximone.
DR   DrugBank; DB05266; Ibudilast.
DR   DrugBank; DB00922; Levosimendan.
DR   DrugBank; DB00235; Milrinone.
DR   DrugBank; DB01303; Oxtriphylline.
DR   DrugBank; DB00277; Theophylline.
DR   DrugBank; DB08811; Tofisopam.
DR   GuidetoPHARMACOLOGY; 1298; -.
DR   iPTMnet; Q14432; -.
DR   PhosphoSitePlus; Q14432; -.
DR   BioMuta; PDE3A; -.
DR   DMDM; 47117888; -.
DR   EPD; Q14432; -.
DR   MaxQB; Q14432; -.
DR   PaxDb; Q14432; -.
DR   PeptideAtlas; Q14432; -.
DR   PRIDE; Q14432; -.
DR   Ensembl; ENST00000359062; ENSP00000351957; ENSG00000172572.
DR   GeneID; 5139; -.
DR   KEGG; hsa:5139; -.
DR   UCSC; uc001reh.3; human.
DR   CTD; 5139; -.
DR   DisGeNET; 5139; -.
DR   GeneCards; PDE3A; -.
DR   HGNC; HGNC:8778; PDE3A.
DR   HPA; HPA014492; -.
DR   MalaCards; PDE3A; -.
DR   MIM; 112410; phenotype.
DR   MIM; 123805; gene.
DR   neXtProt; NX_Q14432; -.
DR   OpenTargets; ENSG00000172572; -.
DR   PharmGKB; PA33126; -.
DR   eggNOG; ENOG410IEGG; Eukaryota.
DR   eggNOG; ENOG410XT2V; LUCA.
DR   GeneTree; ENSGT00760000119066; -.
DR   HOGENOM; HOG000060144; -.
DR   HOVERGEN; HBG053541; -.
DR   KO; K19021; -.
DR   OMA; LTSPCHS; -.
DR   OrthoDB; EOG091G0BTI; -.
DR   PhylomeDB; Q14432; -.
DR   TreeFam; TF329631; -.
DR   BRENDA; 3.1.4.17; 2681.
DR   Reactome; R-HSA-418457; cGMP effects.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   SABIO-RK; Q14432; -.
DR   SIGNOR; Q14432; -.
DR   ChiTaRS; PDE3A; human.
DR   GenomeRNAi; 5139; -.
DR   PRO; PR:Q14432; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000172572; -.
DR   CleanEx; HS_PDE3A; -.
DR   Genevisible; Q14432; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0004115; F:3',5'-cyclic-AMP phosphodiesterase activity; TAS:Reactome.
DR   GO; GO:0047555; F:3',5'-cyclic-GMP phosphodiesterase activity; TAS:Reactome.
DR   GO; GO:0030552; F:cAMP binding; IEA:Ensembl.
DR   GO; GO:0004119; F:cGMP-inhibited cyclic-nucleotide phosphodiesterase activity; TAS:ProtInc.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006198; P:cAMP catabolic process; IDA:UniProtKB.
DR   GO; GO:0019933; P:cAMP-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0071321; P:cellular response to cGMP; IDA:UniProtKB.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEP:UniProtKB.
DR   GO; GO:0019934; P:cGMP-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0016101; P:diterpenoid metabolic process; IEA:Ensembl.
DR   GO; GO:0006629; P:lipid metabolic process; TAS:ProtInc.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0043116; P:negative regulation of vascular permeability; IMP:UniProtKB.
DR   GO; GO:0001556; P:oocyte maturation; IEA:Ensembl.
DR   GO; GO:0060282; P:positive regulation of oocyte development; IEA:Ensembl.
DR   GO; GO:0043117; P:positive regulation of vascular permeability; IMP:UniProtKB.
DR   GO; GO:0040020; P:regulation of meiotic nuclear division; IEA:Ensembl.
DR   GO; GO:0051591; P:response to cAMP; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   Gene3D; 1.10.1300.10; -; 1.
DR   InterPro; IPR003607; HD/PDEase_dom.
DR   InterPro; IPR002073; PDEase_catalytic_dom.
DR   InterPro; IPR023174; PDEase_CS.
DR   Pfam; PF00233; PDEase_I; 1.
DR   SMART; SM00471; HDc; 1.
DR   PROSITE; PS00126; PDEASE_I; 1.
PE   1: Evidence at protein level;
KW   3D-structure; cAMP; cGMP; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Hydrolase; Membrane;
KW   Metal-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN         1   1141       cGMP-inhibited 3',5'-cyclic
FT                                phosphodiesterase A.
FT                                /FTId=PRO_0000198799.
FT   TRANSMEM     61     81       Helical. {ECO:0000255}.
FT   TRANSMEM    130    150       Helical. {ECO:0000255}.
FT   TRANSMEM    160    180       Helical. {ECO:0000255}.
FT   TRANSMEM    185    205       Helical. {ECO:0000255}.
FT   TRANSMEM    210    230       Helical. {ECO:0000255}.
FT   TRANSMEM    232    252       Helical. {ECO:0000255}.
FT   REGION      728   1086       Catalytic. {ECO:0000250}.
FT   COMPBIAS     95     98       Poly-Ala.
FT   COMPBIAS     99    102       Poly-Glu.
FT   COMPBIAS    288    291       Poly-Arg.
FT   COMPBIAS    440    445       Poly-Thr.
FT   COMPBIAS    870    873       Poly-Ala.
FT   COMPBIAS   1040   1045       Poly-Glu.
FT   COMPBIAS   1121   1125       Poly-Glu.
FT   ACT_SITE    752    752       Proton donor. {ECO:0000250}.
FT   METAL       756    756       Divalent metal cation 1. {ECO:0000250}.
FT   METAL       836    836       Divalent metal cation 1. {ECO:0000250}.
FT   METAL       837    837       Divalent metal cation 1. {ECO:0000250}.
FT   METAL       837    837       Divalent metal cation 2. {ECO:0000250}.
FT   METAL       950    950       Divalent metal cation 1. {ECO:0000250}.
FT   MOD_RES     312    312       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     492    492       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     520    520       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     524    524       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9Z0X4}.
FT   MOD_RES    1033   1033       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9Z0X4}.
FT   MOD_RES    1036   1036       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q9Z0X4}.
FT   VARIANT      12     12       D -> N (in dbSNP:rs12305038).
FT                                {ECO:0000269|PubMed:8695850}.
FT                                /FTId=VAR_059543.
FT   VARIANT     445    445       T -> A (in HTNB; gain of function
FT                                mutation with increased cAMP-hydrolytic
FT                                activity; dbSNP:rs794726865).
FT                                {ECO:0000269|PubMed:25961942}.
FT                                /FTId=VAR_073869.
FT   VARIANT     445    445       T -> N (in HTNB; gain of function
FT                                mutation with increased cAMP-hydrolytic
FT                                activity; dbSNP:rs794726864).
FT                                {ECO:0000269|PubMed:25961942}.
FT                                /FTId=VAR_073870.
FT   VARIANT     445    445       T -> S (in HTNB; gain of function
FT                                mutation with increased cAMP-hydrolytic
FT                                activity). {ECO:0000269|PubMed:25961942}.
FT                                /FTId=VAR_073871.
FT   VARIANT     447    447       A -> T (in HTNB; gain of function
FT                                mutation with increased cAMP-hydrolytic
FT                                activity; dbSNP:rs794726866).
FT                                {ECO:0000269|PubMed:25961942}.
FT                                /FTId=VAR_073872.
FT   VARIANT     447    447       A -> V (in HTNB; gain of function
FT                                mutationwith increased cAMP-hydrolytic
FT                                activity; dbSNP:rs794726867).
FT                                {ECO:0000269|PubMed:25961942}.
FT                                /FTId=VAR_073873.
FT   VARIANT     449    449       G -> V (in HTNB; gain of function
FT                                mutation with increased cAMP-hydrolytic
FT                                activity; dbSNP:rs794726868).
FT                                {ECO:0000269|PubMed:25961942}.
FT                                /FTId=VAR_073874.
FT   CONFLICT     69     69       S -> C (in Ref. 3; AAB18673).
FT                                {ECO:0000305}.
FT   CONFLICT    110    110       G -> A (in Ref. 3; AAB18673).
FT                                {ECO:0000305}.
FT   CONFLICT    354    371       HGLITDLLADPSLPPNVC -> TASLPTSWQTLLFHQTCA
FT                                (in Ref. 3 and 4; CAA06304).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1141 AA;  124979 MW;  E69504130F39EFEA CRC64;
     MAVPGDAARV RDKPVHSGVS QAPTAGRDCH HRADPASPRD SGCRGCWGDL VLQPLRSSRK
     LSSALCAGSL SFLLALLVRL VRGEVGCDLE QCKEAAAAEE EEAAPGAEGG VFPGPRGGAP
     GGGARLSPWL QPSALLFSLL CAFFWMGLYL LRAGVRLPLA VALLAACCGG EALVQIGLGV
     GEDHLLSLPA AGVVLSCLAA ATWLVLRLRL GVLMIALTSA VRTVSLISLE RFKVAWRPYL
     AYLAGVLGIL LARYVEQILP QSAEAAPREH LGSQLIAGTK EDIPVFKRRR RSSSVVSAEM
     SGCSSKSHRR TSLPCIPREQ LMGHSEWDHK RGPRGSQSSG TSITVDIAVM GEAHGLITDL
     LADPSLPPNV CTSLRAVSNL LSTQLTFQAI HKPRVNPVTS LSENYTCSDS EESSEKDKLA
     IPKRLRRSLP PGLLRRVSST WTTTTSATGL PTLEPAPVRR DRSTSIKLQE APSSSPDSWN
     NPVMMTLTKS RSFTSSYAIS AANHVKAKKQ SRPGALAKIS PLSSPCSSPL QGTPASSLVS
     KISAVQFPES ADTTAKQSLG SHRALTYTQS APDLSPQILT PPVICSSCGR PYSQGNPADE
     PLERSGVATR TPSRTDDTAQ VTSDYETNNN SDSSDIVQNE DETECLREPL RKASACSTYA
     PETMMFLDKP ILAPEPLVMD NLDSIMEQLN TWNFPIFDLV ENIGRKCGRI LSQVSYRLFE
     DMGLFEAFKI PIREFMNYFH ALEIGYRDIP YHNRIHATDV LHAVWYLTTQ PIPGLSTVIN
     DHGSTSDSDS DSGFTHGHMG YVFSKTYNVT DDKYGCLSGN IPALELMALY VAAAMHDYDH
     PGRTNAFLVA TSAPQAVLYN DRSVLENHHA AAAWNLFMSR PEYNFLINLD HVEFKHFRFL
     VIEAILATDL KKHFDFVAKF NGKVNDDVGI DWTNENDRLL VCQMCIKLAD INGPAKCKEL
     HLQWTDGIVN EFYEQGDEEA SLGLPISPFM DRSAPQLANL QESFISHIVG PLCNSYDSAG
     LMPGKWVEDS DESGDTDDPE EEEEEAPAPN EEETCENNES PKKKTFKRRK IYCQITQHLL
     QNHKMWKKVI EEEQRLAGIE NQSLDQTPQS HSSEQIQAIK EEEEEKGKPR GEEIPTQKPD
     Q
//
